TipRanks (Fri, 7-Feb 8:45 AM ET)
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
TipRanks (Thu, 6-Feb 7:09 AM ET)
Market Chameleon (Wed, 5-Feb 3:40 AM ET)
Globe Newswire (Wed, 5-Feb 7:00 AM ET)
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
Globe Newswire (Thu, 30-Jan 7:00 AM ET)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Thu, 16-Jan 7:00 AM ET)
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
Globe Newswire (Mon, 13-Jan 7:00 AM ET)
Globe Newswire (Wed, 8-Jan 7:00 AM ET)
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 17-Dec 7:00 AM ET)
Globe Newswire (Wed, 4-Dec 7:00 AM ET)
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Eyepoint Pharmaceuticals trades on the NASDAQ stock market under the symbol EYPT.
As of February 11, 2025, EYPT stock price declined to $6.03 with 121,817 million shares trading.
EYPT has a beta of 1.29, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.03 to the broad based SPY ETF.
EYPT has a market cap of $411.55 million. This is considered a Small Cap stock.
Last quarter Eyepoint Pharmaceuticals reported $11 million in Revenue and -$.54 earnings per share. This beat revenue expectation by $594,000 and exceeded earnings estimates by $.01.
In the last 3 years, EYPT traded as high as $30.99 and as low as $2.19.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.
EYPT has underperformed the market in the last year with a price return of -79.1% while the SPY ETF gained +21.9%. EYPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.2% and -24.8%, respectively, while the SPY returned +1.3% and +0.8%, respectively.
EYPT support price is $5.87 and resistance is $6.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.